<qa>  What is the baseline rate of renal decline?Subjects will be randomized 1:1 to the Active Treatment Group or the Deferred Treatment Group following renal biopsy. Subjects in the Active Treatment Group will receive their first NKA injection as soon as the NKA product is manufactured and shipped to the clinical site. After 3 months 12 weeks, a second injection will be given, as appropriate. In contrast, subjects in the Deferred Treatment Group will undergo a period of observation after renal biopsy. During this time, they will receive contemporaneous, standard-of-care therapy for CKD while undergoing follow-up evaluations every 3 months similar to subjects in the Active Treatment Group. After 12-18 months maximum, subjects from the Deferred Treatment Group will receive a series of up to two NKA injections given 3 months 12 weeks apart, as appropriate. Consequently, the study design includes a randomized control group receiving standard-of-care treatment for the first 12-18 months and a randomized, active treatment group receiving up to two NKA injections and follow-up evaluations during the same period of time. In addition, each subjects baseline rate of renal decline, based on adequate historical, clinical data obtained 18 months prior to NKA injection, will serve as a comparator for monitoring the rate of progression of renal insufficiency over time. 